Partners In Health, Boston, Massachusetts, USA.
Interactive Research and Development, Karachi, Pakistan.
Clin Infect Dis. 2020 Jul 11;71(2):415-418. doi: 10.1093/cid/ciz1084.
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
德拉马尼有望有效对抗高度耐药的结核分枝杆菌菌株，但在全球范围内的应用进展缓慢。在 END TB（扩大结核病新药市场）观察性研究中，该研究纳入了接受德拉马尼作为多药方案一部分的大量异质患者队列，80%的参与者在 6 个月内实现了痰培养转阴。临床试验注册。NCT02754765。
